Am J Med Genet B Neuropsychiatr Genet
C.ZieglerC
Aroda, M.D., from Brigham and Women's Hospital in Boston, and colleagues randomly assigned adults with type 2 diabetes inadequately controlled with diet and exercise to receive once-weekly subcutaneous cagrilintide 2.4 mg plus semaglutide 2.4 mg, cagrilintide 1.0 mg plus semaglutide 1.0 mg, or placebo for 40 weeks (62, 63, and 64 participants, respectively)
2021 Aug 16;13(8)
The progression of ALS is driven by a complex interplay among astrocyte abnormalities, chronic neuroinflammation, and TDP-43 aggregation, forming a unique web of interconnected pathologies
These practical, flexible protocols can be applied whether you are working from home, in an office or on the road